Technology
Health
Biotechnology

Selecta Biosciences

$2.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-8.94%) Today
+$0.01 (0.45%) After Hours

Why Robinhood?

You can buy or sell SELB and other stocks, options, ETFs, and crypto commission-free!

About

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. Read More The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Employees
39
Headquarters
Watertown, Massachusetts
Founded
2007
Market Cap
110.18M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
324.26K
High Today
$2.57
Low Today
$2.22
Open Price
$2.50
Volume
88.29K
52 Week High
$16.55
52 Week Low
$1.41

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Research And Development
Gene Therapies
Pharmaceutical

News

Seeking AlphaMay 14

Selecta Biosciences, Inc. CEO Carsten Brunn on Q1 2019 Results - Earnings Call Transcript

Selecta Biosciences, Inc. (NASDAQ:SELB) Q1 2019 Results Conference Call May 9, 2019 8:30 AM ET Company Participants Elona Kogan - General Counsel & Corporate Secretary Carsten Brunn - CEO Stephen Smolinski - CCO Conference Call Participants Difei Yang - Mizuho Securities Derek Archila - Stifel Operator Thank you for holding. Welcome to the Selecta Biosciences First Quarter Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section o...

135
Associated PressMay 2

Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call

WATERTOWN, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it plans to issue its first quarter 2019 financial results before the open of the U.S. financial markets on Thursday, May 09, 2019. At 8:30 a.m. ET that day, Selecta will host a conference call and live audio ...

212

Earnings

-$0.88
-$0.69
-$0.50
-$0.31
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.35 per share
Actual
-$0.31 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.